NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

Contributed by: GlobeNewswire

Tags

Ultragenyx

More Like This

PR Newswire associated0

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older

PR Newswire associated0

The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)

PR Newswire associated0

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

Vertex Announces Extended Long-Term Reimbursement Agreement with NHS England for Access to Cystic Fibrosis Medicines KAFTRIO®, SYMKEVI® and ORKAMBI®

NICE Enables Access to First Treatment That Targets the Underlying Pathophysiology of Rare Disease X-Linked Hypophosphataemia (XLH) in Adults1

PR Newswire associated0

Advancing Bone Health: European Commission Approves Biocon Biologics' Denosumab Biosimilars

PR Newswire associated0

Vaderis Therapeutics Announces The New England Journal of Medicine Publishes Engasertib Proof-of-Concept and Long-Term Extension Results, Highlighting the Therapy's Potential for Patients with Hereditary Hemorrhagic Telangiectasia

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England